Suraj Samtani: Real-World Study of first Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma

Suraj Samtani, Medical Oncologist at Harvard Medical School, shared a post on X, about recent paper published in Clinical Lung Cancer:

Efficacy of First-Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Authors: Diego Enrico, Juan Elias Gomez, Danilo Aguirre, Natalia Soledad Tissera, Florencia Tsou, Carmen Pupareli, Delfina Peralta Tanco, Federico Waisberg, Andrés Rodríguez, Manglio Rizzo, Nicolás Minatta, Picon Rafael, Luis Basbus, Lorena Lupinacci, Diego Kaen, Mauro Ramos, Virginia Bluthgen, Nicolas Castagneris, María Pía Coppola, Alejandra Scocimarro, María Florencia Guerra, Aldo Perfetti, Patricio Levit, Marco Galvez-Nino, Luis Mas, Leonardo Rojas, Jairo Zuluaga, Matías Chacón, Luis Corrales, Suraj Samtani, Oscar Arrieta, Andrés Cardona, Jordi Remon, Claudio Martín.

”Glad to share our latest article Real-World Study of 1st Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma.

A Great collaboration of many great colleagues led by Diego Enrico.”

Source: Suraj Samtani/X